Fintel reports that on August 16, 2023, JP Morgan maintained coverage of Generation Bio (NASDAQ:GBIO) with a Neutral recommendation. As of August 2, 2023, the average one-year price target for ...

Bluebird Bio's Q3 EPS loss was 31 cents, beating consensus estimates of a 36-cent loss. Bluebird Bio's cash balance is $118.7 million, providing a runway into Q1 2025. PPI and Industrial Production ...

bluebird bio (NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations ...

Fintel reports that on August 15, 2024, JP Morgan downgraded their outlook for bluebird bio (MUN:BLE) from Overweight to Neutral. As of December 21, 2023, the average one-year price target for ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that Ivan Dimov, ...